Cover Image
市場調查報告書

美國的搭配診斷市場趨勢與分析

US Companion Diagnostics Market Trends and Insights

出版商 Frost & Sullivan 商品編碼 300902
出版日期 內容資訊 英文 121 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
美國的搭配診斷市場趨勢與分析 US Companion Diagnostics Market Trends and Insights
出版日期: 2014年04月22日 內容資訊: 英文 121 Pages
簡介

在搭配診斷市場分析中,需要包含標靶藥物的開發業者和搭配診斷實驗的開發業者雙方。

本報告提供美國的搭配診斷市場相關調查分析、新的藥物分類與臨床標記的新興機會等,以市場的重要的趨勢為焦點,也包含新興治療領域,為您概述為以下內容。

摘要整理

市場概要與趨勢

產品分析:BRAF、EGFR、KRAS

藥物開發的伴同性生物標記的機會

競爭策略

美國的法規概要

附錄

  • 伴同性生物標記的治療開發平台:各製藥廠
  • 伴同性生物標記的治療開發平台:各癌症類型

關於Frost&Sullivan

目錄
Product Code: 9837-00-7C-00-00

Technological Advances and Promising New Drug Classes Create New Market Opportunities

A complete companion diagnostic market analysis must include both developers of targeted drugs and developers of companion diagnostic tests. This research deliverable discusses important trends in the U.S. companion diagnostics market including emerging opportunities with novel drug classes and new clinical markers like circulating tumor cells. Emerging therapeutic areas beyond oncology for companion diagnostics are also discussed along with key competitors, rx-cdx partnerships, regulatory overview, and therapeutic pipelines with companion biomarkers.

Table of Contents

Executive Summary

Market Overview and Trends

Product Analysis: BRAF, EGFR, KRAS

Companion Biomarker Opportunities in Drug Development

Competitive Playbook

US Regulatory Overview

Appendix

  • Therapeutic Pipeline with Companion Biomarker-By Pharmaceutical Company
  • Therapeutic Pipeline with Companion Biomarker-By Cancer Type

The Frost & Sullivan Story

Back to Top